KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Change in Accured Expenses (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Change in Accured Expenses for 13 consecutive years, with $2.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses fell 61.95% to $2.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.5 million, a 35.4% decrease, with the full-year FY2025 number at $5.5 million, down 35.4% from a year prior.
  • Change in Accured Expenses was $2.4 million for Q4 2025 at Xenon Pharmaceuticals, down from $6.1 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $9.2 million in Q2 2024 to a low of -$5.8 million in Q1 2022.
  • A 5-year average of $1.5 million and a median of $2.2 million in 2022 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: soared 875.05% in 2021, then plummeted 744.78% in 2024.
  • Xenon Pharmaceuticals' Change in Accured Expenses stood at $3.8 million in 2021, then surged by 60.14% to $6.0 million in 2022, then plummeted by 61.76% to $2.3 million in 2023, then soared by 168.75% to $6.2 million in 2024, then crashed by 61.95% to $2.4 million in 2025.
  • Per Business Quant, the three most recent readings for XENE's Change in Accured Expenses are $2.4 million (Q4 2025), $6.1 million (Q3 2025), and $869000.0 (Q2 2025).